Danaher Corp Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $25.1B+5.2% YoYTTM through 26 Jun 2026
Net Income $4B+2.7% YoYTTM through 26 Jun 2026
Free Cash Flow $5.5BTTM through 26 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 58.5% |
| EBITDA Margin | 29.0% |
| Operating Margin | 20.4% |
| Net Margin | 16.0% |
Returns
7.6%ROE
4.3%ROA
5.4%ROIC
Balance Sheet Health
Debt / Equity0.51x
Current Ratio1.65x
Net Debt$22.2B
Cash & Equivalents$4.3B
Quality Metrics
Altman Z-Score3.60
Piotroski F-Score4 / 9
FCF Margin21.8%
Rule of 4026.7
Earnings-Beat Rate100.0%
Multi-Year Trend
RevenueFY2025: $24.6B
Diluted EPS$5.63TTMFY2025: $5.05
Dividend
$1.12Per share, FY20260.51%Yield+8.5%5-yr growth
Capital Allocation
R&D Spend$1.6B
Capex Intensity4.7%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Biotechnology | $7.3B | +7.9% | View detailsFor full year 2026, core sales growth is expected to be in the mid-single digit range. |
| Life Sciences | $7.3B | +0.1% | View detailsFor full year 2026, core sales growth is expected to be in the 3.0% to 4.0% range. |
| Diagnostics | $9.9B | +1.6% | View detailsFor full year 2026, core sales growth is expected to be flat to up slightly, with the segment expanded by the acquisition of Masimo Corporation completed in June 2026. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.